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Combined Increased Chemosensitivity to Hypoxia
and Hypercapnia as a Prognosticator in Heart Failure
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Giovanni Iudice, BSC,* Darrel P. Francis, MD, PHD,‡ Antonio Barsotti, MD, PHD,†
Massimo Piepoli, MD, PHD,§ Claudio Passino, MD
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Objectives The aim of the present study was to investigate the prognostic significance of chemosensitivity to hypercapnia in
chronic heart failure (HF).
Background Increased chemosensitivity to hypoxia and hypercapnia has been observed in HF. The potential value of enhanced
chemosensitivity to hypercapnia to risk prediction in systolic HF has not been specifically evaluated.
Methods One hundred ten consecutive systolic HF patients (age 62  15 years, left ventricular ejection fraction [LVEF]
31  7%) underwent assessment of chemosensitivity to hypoxia and hypercapnia (rebreathing technique) and
were followed up for a median period of 29 months (range 1 to 54 months). The end point was a composite of
cardiac death and aborted cardiac death (ventricular tachyarrhythmia treated by cardioverter-defibrillator).
Results At baseline, 31 patients (28%) had enhanced chemosensitivity to both hypoxia and hypercapnia. Although they
had the same LVEF as the 43 patients (39%) with normal chemosensitivity, they were more symptomatic (New
York Heart Association functional class), had higher plasma brain natriuretic peptide and norepinephrine,
steeper regression slope relating minute ventilation to carbon dioxide output (VE/VCO2 slope), more Cheyne-
Stokes respiration, and more ventricular arrhythmias (all p  0.05). Four-year survival was only 49%, in marked
contrast to 100% for patients with normal chemosensitivity (p  0.001). On multivariate analysis, combined
elevation in chemosensitivity was the strongest independent prognostic marker, even when adjusted for univari-
ate predictors (VE/VCO2 slope, Cheyne-Stokes respiration, LVEF, and brain natriuretic peptide, p  0.05).
Conclusions Increased chemosensitivity to both hypoxia and hypercapnia, eliciting neurohormonal derangement, ventilation
instability, and ventricular arrhythmias, is a very serious adverse prognostic marker in HF. (J Am Coll Cardiol
2009;53:1975–80) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.02.030o
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wespite advances in treatment, the prognosis of patients
ith chronic heart failure (HF) is poor (1). Isolated in-
reased chemosensitivity to either hypoxia or hypercapnia is
ssociated with clinical severity in HF, as well as with
ctivation of the adrenergic (2,3) and natriuretic peptide (3)
ystems, unstable ventilatory control (Cheyne-Stokes respi-
ation [CSR]) (3–5), ventilatory inefficiency during exercise
3,6), and ventricular arrhythmias (3–7). Chemosensitiv-
ty to hypoxia and to hypercapnia can be measured
eparately. We have recently found that when both
hemosensitivities are abnormally enhanced (rather than
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Manuscript received September 29, 2008; revised manuscript received February 9,
009, accepted February 16, 2009.nly one), there is worse instability of ventilatory control,
ore neurohormonal activation, and a greater tendency
oward arrhythmia (3).
The independent prognostic significance of increased
hemosensitivity in HF has only been reported once before
8), and the report addressed only the hypoxic chemosen-
itivity. The prognostic significance of increased sensitivity
o hypercapnia has never been investigated. The purpose of
ur study was to evaluate in a cohort of systolic HF patients
hether enhanced chemosensitivity to hypercapnia has a
rognostic significance.
ethods
ubjects and study design. Between September 2003 and
anuary 2007, we prospectively screened 168 HF patients
ith impaired left ventricular systolic function (left ventric-
lar ejection fraction [LVEF] 45%). Exclusion criteria
ere New York Heart Association (NYHA) functional classV, acute coronary syndrome within 6 months before
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monary disease, history of obstruc-
tive sleep apnea, and therapy with
morphine or derivates, theophyl-
line, oxygen, benzodiazepines, or
acetazolamide. One hundred ten
patients matched the entry criteria,
all on stable optimal pharmacolog-
ical and device treatment (Table 1)
for more than 1 month.
They were evaluated during a
period of at most 5 days, includ-
ing evaluation of chemosensitiv-
ity to hypoxia and to hypercapnia
by rebreathing technique (9,10),
as previously described (3), assay
of brain natriuretic peptide (BNP)
(Shionoria BNP, Shionogi, Ja-
pan) and norepinephrine (HPLC
HCL-725 CA, Tosoh Corpora-
tion, Tokyo, Japan), symptom-
limited maximal cardiopulmonary
exercise test (Vmax, Sensormedics,
orba Linda, California), standard Doppler echocardiography,
4-h electrocardiographic recording (Elamedical, Montrouge,
rance), 20-min daytime polygraphy (3,10), and standard
octurnal polysomnography (E-series 2, Compumedics, Mel-
ourne, Australia) for CSR assessment. The study protocol
as approved by the Institutional Ethics Committee of the G.
onasterio Foundation CNR-Regione Toscana and CNR
nstitute of Clinical Physiology, Pisa, Italy, and informed
onsent was obtained from all subjects.
Abbreviations
and Acronyms
BNP  brain natriuretic
peptide
CI  confidence interval
CSR  Cheyne-Stokes
respiration
HCVR  hypercapnic
ventilatory response
HF  heart failure
HR  hazard ratio
HVR  hypoxic ventilatory
response
LVEF  left ventricular
ejection fraction
NYHA  New York Heart
Association
VE/VCO2 slope  regression
slope relating minute
ventilation to carbon
dioxide output
VO2  oxygen uptake
haracteristics of Patients
Table 1 Characteristics of Patients
HF Patients (n  110)
Age (yrs) 62 15
Male (%) 83
BMI (kg·m2) 27.1 4.2
ECrCl (ml·min1) 77.0 30.8
Ischemic/idiopathic/secondary (%) 47/40/13
Atrial fibrillation (%) 25
NYHA functional class I to II/III (%) 68/32
LVEF (%) 31.1 7.1
HVR (l·min1·%SaO2
1) 0.67 0.45
HCVR (l·min1·mm Hg1) 0.80 0.41
Furosemide (%) 80
Beta-blockers (%) 86
ACEI-ARB (%) 78
Spironolactone (%) 42
CRT (%) 27
ICD (%) 17
nless noted, values are expressed as mean  SD or median (interquartile range).
ACEI  angiotensin-converting enzyme inhibitors; ARB  angiotensin receptor blockers; BMI 
ody mass index; CRT  cardiac resynchronization therapy; ECrCl  estimated creatinine clear-
nce from Cockroft-Gault formula; HCVR  hypercapnic ventilatory response; HF  heart failure;r
VR  hypoxic ventilatory response; ICD  implantable cardioverter-defibrillator; LVEF  left
entricular ejection fraction; NYHA  New York Heart Association.ollow-up and documentation of end points. Patients
ere followed up at the outpatient clinic of our hospital, and
heir outcome status was determined from the medical
ecords or telephone interviews. The composite end point
as death attributable to cardiac cause (sudden death,
rogressive HF–related death, acute myocardial infarction)
r life-threatening ventricular tachyarrhythmia requiring
ardioverter-defibrillator shock. Patients who died of non–
ardiac-related causes or who underwent heart transplanta-
ion were considered censored at the time of the event.
tatistical analysis. Statistical analysis was performed us-
ng the SPSS program (version 13.0, 1989 to 2004, SPSS
nc., Chicago, Illinois). Values are presented as mean SD,
r median and interquartile range (IQR) (for values with
on-normal distribution); variables with a skewed distribu-
ion were logarithmically transformed before further analy-
is. A value of p  0.05 was considered significant.
Mean differences among groups were evaluated through
he unpaired Student t test or analysis of variance with
onferroni post-hoc correction, when appropriate. Discrete
ariables were compared by the chi-square test with Yates
orrection or the Fisher exact test.
The candidate independent variables used for univariate
ox proportional analysis were selected on the basis of the
trength of association with outcome shown by previous
tudies in similar populations: age; sex; body mass index;
erum creatinine level; HF etiology; atrial fibrillation;
YHA functional class; LVEF; left ventricular dimensions;
eak oxygen uptake (VO2)/kg; regression slope relating
inute ventilation to carbon dioxide output (VE/VCO2);
hemosensitivity to: 1) hypoxia, 2) hypercapnia, and 3) both
ypoxia and hypercapnia; diurnal and nocturnal CSR;
lasma BNP; norepinephrine and renin activity; and 24-h
eat-to-beat standard deviation of normal RR intervals.
nly chemosensitivity, among the continuous variables, was
onsidered as a dichotomized variable, with cutoff values of
.77 l·min1·%SaO2
1 for hypoxic ventilatory response
HVR) and 0.79 l·min1·mm Hg1 for hypercapnic venti-
atory response (HCVR), as previously described (3). All
ariables significantly associated with outcome at univariate
nalysis were then entered in multivariate analysis, limited
o a maximum of 2 covariates because of the number of
vents. Survival was estimated by the product-limit Kaplan-
eier method and log-rank statistics.
esults
verall, 43 patients (39%) showed normal chemosensitivity,
hereas 67 patients (61%) showed increased hypoxic and/or
ypercapnic chemosensitivity. Isolated increased HVR and
CVR was found in 13 (12%) and 23 (21%) patients, and
ombined increased HVR and HCVR was present in 31
atients (28%). Patients with increased chemosensitivity did
ot differ from those with normal chemosensitivity with
egard to age, sex, left ventricular dimensions or function,
enal function (Table 2), pulmonary function, and resting
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May 26, 2009:1975–80 Chemoreflex and Prognosis in HFrterial gas analysis values, but showed higher NYHA
unctional class (Table 2). A combined HVR and HCVR
nhancement was associated with neurohormonal activation
increased plasma norepinephrine concentration and BNP
nd N-terminal part of the pro–B-type natriuretic peptide
evels) (Table 2), despite a similar degree of left ventricular
ystolic dysfunction.
In addition, compared with patients with normal chemo-
ensitivity, patients with combined HVR and HCVR en-
ancement showed lower functional capacity (peak VO2/kg)
nd ventilatory efficiency (higher VE/VCO2 slope). Those in
inus rhythm (n  71) also showed lower heart rate
ariability and a greater prevalence of paroxysmal atrial
brillation and nonsustained ventricular tachycardia on
4-h electrocardiographic monitoring (Table 2). Finally, all
F patients with normal chemosensitivity had a normal
reathing pattern, whereas daytime and nighttime CSR
ccurrence increased progressively from isolated up to com-
ined enhanced HVR or HCVR (Table 2).
rognostic value of chemoreflex. No patient was lost to
ollow-up, which lasted for a median period of 29 months
range 1 to 54 months). Five patients died of noncardiac
auses (2 stroke; 3 cancer), 11 of cardiac causes (4 sudden
eaths; 4 progressive HF; 3 myocardial infarction), and 4
atients were appropriately treated by the implantable
ardioverter-defibrillator for ventricular fibrillation. Thus,
5 patients (14%) had major cardiac events with a median
ime to an event of 16 months (range 1 to 45 months).
ctuarial early (6 months) and late (4 years) event-free
urvival rates were 94%, and 79%, respectively.
There was no difference in age, sex, pharmacological and
linical Characteristics, Neurohormonal Profile, Functional Capacite til tory Efficiency, and Arrhyth ias According to Chemosensitiv
Table 2 Clinical Characteristics, Neurohormonal Profile, FunctiVentilatory Efficiency, and Arrhythmias According to C
Normal HVR and HCVR
n (%) 43 (39)
Age (yrs) 60 15
Male, n (%) 31 (72)
BMI (kg·m2) 27.0 4.8
ECrCl (ml·min1) 82.4 36.1
NYHA functional class III (%) 18
LVEF (%) 32.9 6.8
LV end-diastolic diameter (mm) 60.1 8.1
Norepinephrine (ng·l1) 300 (186–543)
BNP (ng·l1) 67 (33–212)
Peak VO2/kg (ml·min
1·kg1) 14.2 6.0
VE/VCO2 slope 34.1 5.9
SDNN (ms) 106.5 41.5
Atrial fibrillation (%) 7
NSVT (%) 26
Diurnal CSR (%) 0
Nocturnal AHI (n/h) 3.0 (0.9–5)
alues are expressed as mean SD for continuous normally distributed variables, as median (25th
p  0.05, †p  0.001, §p  0.01 versus normal HVR and HCVR. ‡p  0.05 versus increased H
AHI  apnea-hypopnea index; BNP  brain natriuretic peptide; CSR  Cheyne-Stokes respiratio
R intervals; VE/VCO2 slope  regression slope relating minute ventilation to carbon dioxide outpuevice treatment, HF etiology, and peak VO2 between 0atients with events and those without (all p  0.1).
atients who had major cardiac events had a lower LVEF
27.8  5.3% vs. 31.7  7.2%, p  0.03), higher chemo-
ensitivity to hypercapnia (1.03  0.28 l·min1·mm Hg1
s. 0.77  0.41 l·min1·mm Hg1, p  0.02), higher
E/VCO2 slope (44.2 8.5 vs. 37.8 8.6, p 0.02), higher
ncidence of daytime CSR (65% vs. 8%, p  0.001), and
orse neurohormonal status, as expressed by increased
lasma levels of BNP (442 [IQR: 246 to 671] ng·l1 vs. 138
IQR: 47 to 182] ng·l1, p  0.001), norepinephrine (588
IQR: 481 to 782] ng·l1 vs. 412 [IQR: 268 to 675] ng·l1,
 0.004), and plasma renin activity (3.1 [IQR: 1.1 to
3.5] ng·l1·h1 vs. 1.2 [IQR: 0.4 to 3.3] ng·l1·h1, p 
.04). In this subset, we observed nonsignificant trends to
orse NYHA functional class (III) (30% vs. 10%, p 
.06), nocturnal CSR, as expressed by the apnea-hypopnea
ndex (18.6  8.7 vs. 11.0  10.7, p  0.07), and
hemosensitivity to hypoxia (0.85 0.41 l·min1·%SaO2
1
s. 0.64  0.45 l·min1·%SaO2
1, p  0.09).
urvival analysis. A Kaplan-Meier analysis was performed
or early (6-month) and late (4-year) survival. Early and late
vent-free survivals were 87% and 49%, respectively, for
atients with higher combined chemosensitivity, compared
ith 96% and 84% for patients with isolated enhanced
ypercapnic sensitivity, and 100% and 88% in patients with
solated hypoxic hypersensitivity. No patient with normal
hemosensitivity had cardiac events (overall log-rank among
he 4 subgroups: 20.02, p  0.001) (Fig. 1).
nivariate analysis. The following clinical variables were
elated to the occurrence of major cardiac events: LVEF
hazard ratio [HR]: 0.90, 95% confidence interval [CI]:
Capacity,
sensitivity
ased HVR Increased HCVR Increased HVR and HCVR
12) 23 (21) 31 (28)
2 14 60 18 68 9
92) 19 (82) 29 (94)
4 4.3 26.0 4.3 27.4 2.8
1 28.5 80.5 31.1 70.1 20.5
31 39 45*
9 9.3 29.8 6.7 29.5 6.4
1 10.4 63.7 8.2 63.3 8.9
288–562) 459 (309–777) 642 (393–778)†
39–270) 214 (108–376)* 325 (200–710)†‡
7 7.4 11.7 5.6 10.5 2.8*
7 11.4 39.6 6.7 45.2 8.2†
6 57.2 85.1 28.4 63.7 39.8§
15 9 45†‡
53 48 60§
15 14 58†
2.1–14.0) 13.0 (3.1–15.9) 19.0 (10.8–29.3)§
percentile) for continuous non-normally distributed variables, and as percent for categorical data.
e. p  0.05 versus increased HCVR alone.
left ventricular; NSVT  nonsustained ventricular tachycardia; SDNN  standard deviation of all
oxygen uptake; other abbreviations as in Table 1.y,ity
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Chemoreflex and Prognosis in HF May 26, 2009:1975–805% CI: 1.01 to 1.13, p  0.02), chemosensitivity to both
ypoxia and hypercapnia (HR: 7.94, 95% CI: 2.52 to 25.01,
 0.001), occurrence of diurnal CSR (HR: 6.02, 95% CI:
.15 to 16.87, p  0.001), and higher BNP plasma level
HR: 2.62, 95% CI: 1.54 to 4.45, p  0.001).
ultivariate analyses. On bivariate analyses, we found
hat augmented chemosensitivity to both hypoxia and hy-
ercapnia was a marker of poor prognosis independent of
he other univariate predictors (Table 3). Combined en-
anced chemosensitivity remained an independent predictor
f death, even when adjusted for VE/VCO2 slope, diurnal
SR, LVEF, and BNP (Table 3).
iscussion
he novel finding of this study is that in patients with
ystolic HF, enhanced chemosensitivity to hypercapnia,
specially when combined with hypersensitivity to hypoxia,
s a strong, independent predictor of cardiac death, includ-
ng aborted death (cardioverted life-threatening tachyar-
hythmias). Patients with normal chemosensitivity, despite
similar degree of left ventricular dysfunction, were instead
pared from fatal events.
There is growing evidence that the enhancement of
hemosensitivity (7) may be important in HF, as well as
ithdrawal of the inhibitory baroreflex stimulus (11,12), by
ncreasing sympathetic drive (13,14). There is also growing
vidence for a key role of central afferent sympathoexcitation
n modulating chemoreflex sensitivity and medullary auto-
omic centers (15,16). Therefore, the association between
100
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Figure 1 Chemosensitivity and Survival in Heart Failure
Kaplan-Meier survival plot in heart failure patients with normal chemosensitivity
(norm HVR & HCVR) compared with patients with augmented chemosensitivity
to: hypoxia alone (1HVR), hypercapnia alone (1HCVR), and hypoxia and hyper-
capnia combined (1HVR & HCVR). HCVR  hypercapnic ventilatory response;
HVR  hypoxic ventilatory response.ltered chemosensitivity and increased sympathetic drive Cight be causal in both directions, and might therefore be
ble to engender a self-sustaining vicious cycle. We found
hat the worst clinical status, neurohormonal activation (as
xpressed by higher norepinephrine, plasma renin activity,
nd natriuretic peptide levels), and ventilatory derangement
at rest with CSR occurrence, and during exercise with
orse ventilatory efficiency) were observed in the subset of
atients with combined enhancement of chemosensitivity to
ypoxia and hypercapnia, confirming our previous observa-
ions in a smaller group (3).
Notably, all of these variables are acknowledged prognos-
ic markers in HF (17–21), and combined chemosensitivity,
onsidered in our study for the first time, was the strongest
ndependent predictor of cardiac death and life-threatening
rrhythmias. The grim prognostic significance of aug-
ented chemosensitivity to hypoxia and hypercapnia may
esult mainly from its excitatory effects on the sympathetic
ervous system through a direct excitatory input (2,22), and
ndirectly by means of the CSR-related hypoxia phases
7,23). In a study conducted before beta-blockade became
outine therapy, Ponikowski et al. (8) observed that chemo-
ensitivity to hypoxia was an independent prognostic marker
n HF patients. This apparent discrepancy may be explained
y the extensive use of beta-blockers in our more recent
opulation with a putative more selective effect on periph-
ral chemoreceptors. One-half of the events in our popula-
ion were arrhythmic, suggesting sympathovagal imbalance
licited by activated chemoreceptors. In this respect, we
ound in patients with combined enhancement of chemo-
ensitivity both reduced heart rate variability and higher
ccurrence of atrial fibrillation and nonsustained ventricular
achycardia, in agreement with previous findings (24). More
mportantly, however, the study by Ponikowski et al. (8) did
ot measure hypercapnic chemosensitivity, and therefore
ould not distinguish patients with isolated enhanced hy-
ercapnic sensitivity from those with combined chemoreflex
nhancement: we will never know whether it was both
otional subgroups, or only one, that had the increased risk.
e believe our more comprehensive study builds on the
redictors of Major Cardiac Events in HFatien s (Bivariate Cox Proportio al Hazard Analysis)
Table 3 Predictors of Major Cardiac Events in HFPatients (Bivariate Cox Proportional Hazard Analysis)
Variable HR (95% CI) p Value
Augmented HVR and HCVR vs. LVEF
1 Chemosensitivity 6.86 (2.16–21.83) 0.001
LVEF 0.92 (0.85–1.00) 0.050
Augmented HVR and HCVR vs. VE/VCO2 slope
1 Chemosensitivity 8.12 (1.84–35.85) 0.005
VE/VCO2 slope 1.01 (0.94–1.09) 0.749
Augmented HVR and HCVR vs. diurnal CSR
1 Chemosensitivity 4.33 (1.09–19.44) 0.038
CSR 2.25 (0.61–8.28) 0.222
Augmented HVR and HCVR vs. BNP
1 Chemosensitivity 4.26 (1.26–14.47) 0.02
BNP 2.03 (1.15–3.58) 0.014I  confidence interval; HR  hazard ratio; other abbreviations as in Tables 1 and 2.
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May 26, 2009:1975–80 Chemoreflex and Prognosis in HFork of Ponikowski et al. (8) to highlight the importance of
he combined enhancement.
tudy limitations. A limitation of this study is the number
f patients recruited and therefore the relatively small
umber of events observed. Therefore, although we limited
he multivariate analysis to a maximum of 2 covariates,
e cannot exclude the possibility of overfitting models.
uch limitations are common in real-world, hypothesis-
enerating, single-center studies. Attempting to run such a
tudy on a multicenter basis might increase numbers but
ay well be hampered with the likely great difficulty in
stablishing and maintaining equivalence between centers in
ethods (neurohormonal, sleep, cardiopulmonary exercise,
nd chemosensitivity assessment).
Finally, it is a limitation that hypercapnic chemosensitiv-
ty is not routinely measured in clinical practice worldwide.
owever, the rebreathing circuit required is very inexpen-
ive ($50) and is easy to set up at any site where
ardiopulmonary exercise testing is carried out. The tests
an be performed by technicians. If our findings are con-
rmed in other studies, chemosensitivity testing might
ecome a useful, simple, and convenient addition to routine
rognostic evaluation in HF patients. Recognition of the
owerful adverse significance of combined enhanced che-
oreflex sensitivity may stimulate more work into its origin
nd pathophysiology.
onclusions
ncreased sensitivity of chemoreceptors to both hypoxia and
ypercapnia is a powerful and independent predictor of
ortality in HF patients. In the early phase of HF syn-
rome, the chemoreceptors may act in a compensatory way,
riggering autonomic nervous system changes in the cardio-
espiratory system that prevents tissue hypoxia or hyper-
apnia. However, over time, chemoreceptor up-regulation
ight promote a vicious circle eliciting autonomic imbal-
nce, neurohormonal activation, abnormal ventilatory re-
ponses, arrhythmias, and favoring adverse events. Chemo-
eflex overactivation deserves more attention as a potential
pecific therapeutic target in HF, to be treated by novel
harmacological, device-based, or behavioral approaches
15,16,25–27).
eprint requests and correspondence: Dr. Michele Emdin, Car-
iovascular Medicine Department, G. Monasterio Foundation, Via
iuseppe Moruzzi 1, 56124 Pisa, Italy. E-mail: emdin@ifc.cnr.it.
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